Five-year Oncologic Outcomes After Transperitoneal Robotic Partial Nephrectomy for XXXX .

@entity1 @entity8 @entity1625 @entity6841 @entity5 @entity1358
BACKGROUND: @entity1625 ( @entity1625 ) is established as a minimally invasive nephron-sparing technique with excellent perioperative and intermediate oncologic outcomes. However, long-term oncologic outcomes have not been reported to date. OBJECTIVE: To report long-term oncologic outcomes of @entity1625 . DESIGN, SETTING, AND @entity1 : Consecutive @entity1 undergoing @entity1625 from June 2006 to March 2010 were selected from our prospective @entity1625 database. @entity1 with @entity5 , prior @entity6841 , or prior radical nephrectomy and those with follow-up of <1 mo were excluded. INTERVENTION: Transperitoneal @entity1625 . OUTCOMES MEASUREMENTS AND STATISTICAL ANALYSIS: Demographic, perioperative, and postoperative data were analyzed. Overall survival (OS), @entity5 -specific survival (CSS) were evaluated using Kaplan-Meier survival analysis. Univariate logistic regression analysis for overall mortality was performed to evaluate the odds ratio (OR) for variables of interest. RESULTS AND LIMITATIONS: In total, 115 RPNs for @entity1358 were performed in 110 @entity1 . The mean age was 59.8  11.0 yr and the median age-adjusted Charlson comorbidity index (ACCI) was 4 (interquartile range [IQR] 3-5). The median @entity5 size was 2.6cm (IQR 2.0-3.7) and median RENAL score was 7 (IQR 6-9). @entity1358 was present in 67.8% of cases, and two cases (1.7%) had positive surgical margins. Glomerular filtration rate preservation was 87.8% (IQR 74.9-98.1), which translates to 19.1% chronic @entity8 upstaging. The median follow-up was 61.9 mo (IQR 50.9-71.4) and the 5-yr OS, @entity5 , and CSS were 91.1%, 97.8%, and 97.8%, respectively. On univariable logistic regression, ACCI was the only factor associated with a higher risk of overall mortality (OR 1.67, p=0.006). The retrospective design, the high surgical volume at our institution, and the potential selection bias with careful @entity1 selection early in the @entity1625 experience may limit the generalizability of our findings. CONCLUSIONS: This is the first study confirming excellent long-term oncologic outcomes after @entity1625 in a selected cohort of @entity1 . @entity1 SUMMARY: @entity1625 is a relatively recently developed treatment for @entity1358 . This study confirms its safety and reports excellent long-term @entity5 control.
